Delivery Order SPE2DB24D8002-SPE2DB25FJNKY

Award Date 4/1/25
Potential Completion Date 4/2/25
Potential Value $2.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, with a ceiling value of $2,122.33, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is a delivery order under the DLA Troop Support Medical's ECAT Generation V Program, an Indefinite Delivery Contract (IDC) with a maximum value of $999,999,999.00 and a performance period through December 31, 2025. The contract is for the delivery of 4,562,763,308 units of Vyvanse 30 mg capsules, a...
This is a federal contract award from the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $1,201.92, is for the delivery of 100 units of the prescription medication Vyvanse 30 mg capsules. It is a firm fixed-price delivery order contract with a completion date of March 5, 2025. The award is associated with a larger Indefinite Delivery Contract (IDC) held by Dakota Drug, Inc., identified as SPE2DB24D8001 and valued at...
This federal contract award, identified as SPE2DB24D8003|SPE2DB25FJTSL, was issued by the Defense Logistics Agency (DLA) to the prime contractor Dakota Drug, Inc. The contract is for the delivery of VYVANSE 30 MG CAPSULE 100S, a pharmaceutical product, with a total ceiling value of $1,899.17 and a period of performance extending through January 29, 2025. The contract is not set aside and is a Firm Fixed Price Delivery Order. Dakota Drug, Inc. is a self-certified small disadvantaged business...
This federal contract award, identified as SPE2DX15D8001|SPE2DX24FBQHW, was made by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of VYVANSE 30 MG CAPSULE 100S. The contract has a ceiling value of $1,013.63 and a performance period through January 29, 2024. This award is not associated with a set-aside program. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, identified...
This federal contract award, identified as SPE2DX15D8002|SPE2DX24F2TH4, was issued by the Defense Logistics Agency (DLA) Troop Support Medical division to the prime contractor Dakota Drug, Inc. The contract is for the delivery of VYVANSE 50 MG CAPSULE 100S, a pharmaceutical product, to support U.S. Armed Forces medical operations. The contract has a ceiling value of $1,245.99 and a completion date of October 18, 2023. Dakota Drug, Inc. is a self-certified small disadvantaged business...
This federal contract award, identified as SPE2DX15D8002|SPE2DX23F2XH9, was granted to Dakota Drug, Inc., a self-certified small disadvantaged business, by the Defense Logistics Agency (DLA) Troop Support Medical division. The $1,011.24 firm fixed-price delivery order is for the provision of 4560939520 VYVANSE 40 MG CAPSULE 100S, a prescription medication. This contract is not set aside and is part of Dakota Drug, Inc.'s larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of 4562920866 VYVANSE 20 MG CAPSULE 100S. The contract award ID is SPE2DX15D8002|SPE2DX24F2TX1, with a ceiling value of $1,380.43. The contract is a Delivery Order with a Firm Fixed Price pricing type, and the ultimate completion date is November 29, 2023. This award is not associated with a set-aside program. Dakota Drug, Inc. holds a...
This is a federal contract award from the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of 4,563,714,305 units of Vyvanse 40 mg capsules. The contract has a ceiling value of $2,237.18 and a completion date of February 21, 2024. This is a firm fixed-price delivery order contract, and there is no set-aside designation. Dakota Drug, Inc. is a key supplier for the DLA Troop Support Medical division, holding a single-award...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $1,461.76 firm-fixed-price contract is for the delivery of VYVANSE 30 MG CAPSULE 100S, a prescription medication, with a completion date of February 7, 2025. The award is associated with a larger Indefinite Delivery Contract (IDC) held by Dakota Drug, Inc. with the DLA, valued at $999,999,999.00. This IDC, part of the DLA Troop Support Medical's ECAT...
This is a federal contract award from the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, identified as SPE2DX15D8002, is for the delivery of VYVANSE 40 MG CAPSULE 100S, a pharmaceutical product. The contract has a ceiling value of $2,704.11 and a period of performance through November 1, 2023. Dakota Drug, Inc. is a key supplier for the DLA Troop Support Medical division, providing a range of pharmaceutical and medical products...
  • SPE2DB24D8002
    Indefinite Delivery Contract
  • SPE2DB24D8002-SPE2DB25FJNKY
    Delivery Order

This federal contract award, identified as SPE2DB24D8002 and SPE2DB25FJNKY, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of 4,567,763,910 units of the prescription medication VYVANSE 30 MG CAPSULE 100S. The contract has a firm fixed price of $2,577.76 and a period of performance through April 2, 2025.

This award is associated with a larger Indefinite Delivery Contract (IDC) held by Dakota Drug, Inc., identified as SPE2DB24D8001, valued at $999,999,999.00. This IDC is part of the DLA Troop Support Medical's ECAT Generation V Program, which allows the company to provide a wide range of pharmaceutical products, medical supplies, and healthcare equipment to support U.S. Armed Forces medical operations. The contract is not set aside and was awarded on an unrestricted basis, indicating Dakota Drug, Inc.'s competitive standing in the federal marketplace.

Generated 7/1/25, 10:40 AM